Video Library

Assurance in ADC Therapy for HER2+ or HER2-Low mBC
To conclude this series, our seasoned panel describes how clinical trial and practical experiences with antibody drug conjugate therapy for mBC instill their confidence in this therapy.
Key Breast Cancer Abstracts in 2023 and Innovations in Ovarian Function Suppression:
Please join Sara Tolaney, MD, MPH, Dana-Farber Cancer Center, Boston, MA; Erica Stringer-Reasor, MD, University of Alabama, Birmingham; and Matteo Lambertini, MD, PhD, University of Genoa, Italy, as they provide expert commentary on key breast cancer abstracts presented at the 2023 ASCO Annual Meetings that will impact young women with ER+/HER2- breast cancer.
Ovarian Function Suppression in Premenopausal Breast Cancer: Are We Making Progress in Educating Patients on When to Start Therapy and the Length of Therapy?
Hear from two breast cancer nurse navigators, Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, on the progress made in educating patients on when to start ovarian function suppression and the recommended duration of therapy.
How Well Do Patients Tolerate Ovarian Function Suppression? Oncology Nurse Navigators Discuss Their Experience
This Interview with the Innovator video features breast cancer nurse navigators Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, as they discuss ovarian function suppression, how patients tolerate side effects, and educating patients on expectations of treatment.
Ovarian Suppression: What Are Some of the Important Questions That Women Ask?
Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, examine fertility issues associated with ovarian function suppression and the psychosocial impact it has on young breast cancer patients.
Setting Patients’ Expectations When They Are Prescribed Combination Therapy for Premenopausal Breast Cancer
This Interview with the Innovator video features two breast cancer nurse navigators, Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, reviewing combination therapy with ovarian function suppression and its effects in breast cancer patients, including the importance of setting up-front expectations of treatment.
Oncology Nurse Navigators Discuss Their Best Practices to Encourage Premenopausal Breast Cancer Patients to Adhere to Their Therapy
Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, highlight the challenges with ovarian function suppression side effects patients face and explore tactics to encourage adherence to treatment.
Sexual Heath Dysfunction Associated With Ovarian Function Suppression: How Do I Start the Discussion With My Premenopausal Breast Cancer Patient?
Gain insights from Emily Beard, RN, BSN, OCN, CBCN, breast oncology nurse navigator, in this Interview with the Innovator video on communication techniques to discuss sensitive topics with breast cancer patients including sexual health dysfunction associated with ovarian function suppression.
Ovarian Function Suppression Side Effects to Monitor & Report to HCP
In this Interview with the Innovator video, Melissa Simon, BSN, RN, OCN, ONN-CG, and Emily Beard, RN, BSN, OCN, CBCN, discuss common and expected side effects with ovarian function suppression as well as adverse side effects to monitor and report to a healthcare provider.
Navigating Oral Therapy in Breast Cancer: Practice Strategies to Promote Medication Adherence
The Academy of Oncology Nurse & Patient Navigators (AONN+) and Eli Lilly and Company Medical Affairs are pleased to present a live webinar designed to facilitate conversations with patients regarding adherence to breast cancer treatments. Attendees will have an opportunity to participate in a live Q&A following the presentation.
Insights into the Prostate Cancer Imaging Landscape
Dr Steven Rowe continues his discussion of PYLARIFY® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients.
Results from the OSPREY Trial in Pre-Prostatectomy Patients
Dr Steven Rowe continues his discussion of PYLARIFY® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients.
Page 2 of 10
Results 13 - 24 of 114

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country